ODAC Chairman Rebukes Pfizer, Data Monitoring Committee Over Sutent Trial Conduct
Executive Summary
The actions by Pfizer and its independent Data Monitoring Committee in terminating a Sutent clinical trial may have benefitted the study’s placebo subjects, but were a disservice to the larger community of patients with pancreatic neuroendocrine tumors, the chairman of FDA’s Oncologic Drugs Advisory Committee said April 12.
You may also be interested in...
Sutent Pancreatic Tumor Study Shows Regulatory Pitfalls Of Stopping Early
Pfizer’s development of Sutent (sunitinib) for treatment of pancreatic tumors shows the potential pitfalls sponsors face when they decide to terminate clinical trials early due to positive results.
US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory decision-making. The initiative includes demonstration projects on Bayesian analyses, selective safety data collection and point-of-care trials.